113225-07-3

Basic information

• Product Name: 1,2,3,6-TETRAHYDRO-1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-PYRIDINE
• Synonyms: 1,2,3,6-TETRAHYDRO-1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-PYRIDINE;1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE;PYRIDINE, 1,2,3,6-TETRAHYDRO-1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-
• CAS NO: 113225-07-3
• Molecular Formula: C₁₅H₂₁NO₃
• Molecular Weight: 263.33
• Mol File: 113225-07-3.mol

Chemical Properties

• Boiling Point: 395.4°Cat760mmHg
• Flash Point: 117.9°C
• Appearance: /
• Density: 1.074g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.528
• CAS DataBase Reference: 1,2,3,6-TETRAHYDRO-1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,6-TETRAHYDRO-1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-PYRIDINE(113225-07-3)
• EPA Substance Registry System: 1,2,3,6-TETRAHYDRO-1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-PYRIDINE(113225-07-3)

Safety Data

• Hazardous Substances Data: 113225-07-3(Hazardous Substances Data)

Usage

Tetrahydropyridine ring

A six-membered nitrogen-containing ring with four saturated carbon atoms.

Tetrahydropyridine ring

Provides a specific structural framework for potential medicinal properties.

1-methyl group

A methyl group (CH3) attached to the tetrahydropyridine ring at the first position.

4-(2,4,6-trimethoxyphenyl) group

A phenyl ring with three methoxy groups (-OCH3) attached at the 2nd, 4th, and 6th positions, connected to the tetrahydropyridine ring at the 4th position.

Derivative of

Pyridine

Industry application

Pharmaceutical industry

Potential use

Drug candidate for the treatment of various conditions

Multiple methoxy groups

Confer unique electronic and steric properties to the molecule, which may influence its biological activity.

Ongoing research

Exploring potential applications in the field of medicine

Medicinal properties

Attracting attention due to potential therapeutic effects (specific conditions not mentioned in the material provided)

InChI:InChI=1/C15H21NO3/c1-16-7-5-11(6-8-16)15-13(18-3)9-12(17-2)10-14(15)19-4/h5,9-10H,6-8H2,1-4H3

Upstream product

• 1445-73-4 1-Methyl-4-piperidone 
• 621-23-8 1,2,3-trimethoxybenzene 

Downstream Products

• 872057-12-0 1-(N-methylpiperidin-4-yl)-2,4,6-trimethoxybenzene 
• 1366408-11-8 N-(3-((2E)-3-(3-(1,2,3,6-tetrahydro-1-methylpyridin-4-yl)-2,4,6-trimethoxyphenyl)acryloyl)phenyl)benzamide 
• 1366408-12-9 2-fluoro-N-(3-((2E)-3-(3-(1,2,3,6-tetrahydro-1-methylpyridin-4-yl)-2,4,6-trimethoxyphenyl)acryloyl)phenyl)benzamide 
• 1361455-25-5 3-(1,2,3,6-tetrahydro-1-methylpyridin-4-yl)-2,4,6-trimethoxybenzaldehyde 
• 1254302-14-1 1-(3-(1,2,3,6-tetrahydro-1-methylpyridin-4-yl)-2-hydroxy-4,6-dimethoxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one 
• 1254301-88-6 1-(3-(1,2,3,6-tetrahydro-1-methylpyridin-4-yl)-2-hydroxy-4,6-dimethoxyphenyl)-3-(furan-2-yl)-prop-2-en-1-one 
• 1254302-21-0 1-(3-(1,2,3,6-tetrahydro-1-methylpyridin-4-yl)-2-hydroxy-4,6-dimethoxyphenyl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one 
• 1254301-67-1 1-(3-(1,2,3,6-tetrahydro-1-methylpyridin-4-yl)-2-hydroxy-4,6-dimethoxyphenyl)-3-(4-(dimethylamino)phenyl)-prop-2-en-1-one 

Relevant articles and documents

Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models

Phosphatidylinositide 3-kinases (PI3Ks) are widely expressed enzymes involved in membrane signalization pathways. Attempts to administer inhibitors with broad activity against different isoforms have failed due to toxicity. Conversely the PI3Kδ isoform is

PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER

The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of f

Synthesis of newer piperidinyl chalcones and their anticancer activity in human cancer cell lines

Newer tetrahydropyridine chalcones were synthesized and tested for their antioxidant and anticancer activity. These molecules showed significant anticancer activity at IC50 50 μM in human cancer cell lines such as A549 (lung adenocarcinoma),

AN IMPROVED PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES

The present invention relates to a process for the preparation of a key intermediate (as described herein) used in the synthesis of (+)-trans enantiomer of pyrrolidine substituted flavones, represented by the compounds of formula (1) or pharmaceutically a

A PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES

The present invention relates to a process for the preparation of a key intermediate (as described herein) used in the synthesis of (+)-trans enantiomer of pyrrolidine substituted flavones, represented by the compounds of formula (1) or pharmaceutically a

Synthesis and antioxidant, cytotoxicity and antimicrobial activities of novel curcumin mimics

Claisen-Schmidt condensation of 3-(1,2,3,6-tetrahydro-1-methylpyridin-4-yl) -2,4,5-trimethoxybenzaldehyde 3 and various aromatic, heterocyclic and alicyclic amides of 3-aminoacetophenone 6(as) afforded novel curcumin mimics. All the synthesized compounds

CYTOKINE INHIBITORS

The present invention provides compounds represented by general formula (I): wherein, R1; R2, R3, L and T are as defined in the specification, in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, and prodrugs thereof. The invention also relates to processes for the manufacture of compounds of formula (I) and pharmaceutical compositions containing them. The compounds and the pharmaceutical compositions of the present invention are useful in the treatment of a condition or disorder mediated by one or more cytokines selected from Tumor Necrosis Factor-alpha (TNF-oc) and interleukins such as IL-1, IL-6, and IL-8. The present invention further provides a method of treatment of inflammatory disorders by administering a therapeutically effective amount of the said compound of formula (I) or its pharmaceutical composition, to a mammal in need thereof.

NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

The present invention relates to an enantiomerically pure (+)-trans-enantiomer of a compound represented by the following formula (I): wherein R1, R2, R3, R4 and R9 are as defined in the specification; enantiomerically pure intermediates thereof, to processes for the preparation of the enantiomerically pure compound and its intermediates, and to a pharmaceutical composition comprising the enantiomerically pure compound. The compound of formula (I) is useful for the treatment of diseases or disorders mediated by the inhibition of cyclin dependant kinase, such as cancer.

COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER

Disclosed herein are compounds suitable for use as antitumor agents, methods for treating cancer wherein the disclosed compounds are used in making a medicament for the treatment of cancer, methods for treating a tumor comprising, administering to a subject a composition comprising one or more of the disclosed cytotoxic agents, and methods for preparing the disclosed antitumor agents.

ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION

The present invention relates to an enantiomerically pure (+)-trans-enantiomer of a compound represented by the following formula (I): wherein R1, R2, R3, R4 and R9 are as defined in the specification; enantiomerically pure intermediates thereof, to processes for the preparation of the enantiomerically pure compound and its intermediates, and to a pharmaceutical composition comprising the enantiomerically pure compound. The compound of formula (I) is useful for the treatment of diseases or disorders mediated by the inhibition of cyclin dependant kinase, such as cancer.